{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:51Z","timestamp":1789584891840,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pan.2020.07.010","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T02:39:50Z","timestamp":1595644790000},"page":"1183-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-8242","authenticated-orcid":false,"given":"Ryo","family":"Shimoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6876","authenticated-orcid":false,"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-4314","authenticated-orcid":false,"given":"Gakuto","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-707X","authenticated-orcid":false,"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pan.2020.07.010_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"18","key":"10.1016\/j.pan.2020.07.010_bib2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.pan.2020.07.010_bib4","series-title":"Clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm","author":"Japan Neuroendocrine Tumor Society (JNETS)","year":"2015"},{"key":"10.1016\/j.pan.2020.07.010_bib5","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.pan.2020.07.010_bib6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.pan.2020.07.010_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.17925\/EOH.2012.08.4.217","article-title":"Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours","volume":"8","author":"Yao","year":"2012","journal-title":"Eur Oncol Haematol"},{"issue":"4","key":"10.1016\/j.pan.2020.07.010_bib8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.2017-0364","article-title":"Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-world data from the Spanish tumor Registry (R-GETNE)","volume":"23","author":"Nunez-Valdovinos","year":"2018","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.pan.2020.07.010_bib9","first-page":"4573","article-title":"Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells","volume":"60","author":"von Wichert","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.beem.2007.01.006","article-title":"Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma","volume":"21","author":"Yao","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pan.2020.07.010_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10022","key":"10.1016\/j.pan.2020.07.010_bib12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2015.09.004","article-title":"Neuroendocrine tumours \u2013 medical therapy: biological","volume":"30","author":"Rinke","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pan.2020.07.010_bib14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1634\/theoncologist.2011-0458","article-title":"Antitumor effects of somatostatin analogs in neuroendocrine tumors","volume":"17","author":"Sideris","year":"2012","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.pan.2020.07.010_bib15","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"1\u20132","key":"10.1016\/j.pan.2020.07.010_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2007.08.012","article-title":"Somatostatin\/somatostatin receptor signalling: phosphotyrosine phosphatases","volume":"286","author":"Florio","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1634\/theoncologist.2017-0622","article-title":"Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: the GETNE1003_EVERLAR study","volume":"24","author":"Capdevila","year":"2019","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.pan.2020.07.010_bib19","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.28726","article-title":"Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study","volume":"120","author":"Bajetta","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pan.2020.07.010_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.pan.2020.07.010_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.pan.2020.07.010_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/biomet\/70.3.659","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Gordon Lan","year":"1983","journal-title":"Biometrika"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320302271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320302271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:09:28Z","timestamp":1761408568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390320302271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1424390320302271"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2020.07.010","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}